Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks

Amarin (NASDAQ: AMRN) is a drug company that is in a particularly precarious position. This fact is highlighted by the company's recent move to restructure its operations in an effort to cut costs. And Vascepa, the one drug it has to sell, is already facing generic competition in the United States. Most investors would be better off with a larger drug company.Perhaps the most positive thing about Amarin is its balance sheet. The company is carrying no long-term debt, has a cash balance of nearly $135 million, and owns short-term investments worth just under $168 million. In short, it is in a very strong financial position and can likely sustain its business for years to come.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool